Compare Fubotv Inc (FUBO) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Globus Medical Inc. Class A Common Stock — how do they compare? Fubotv Inc trades at $8.22 (market cap $894.32M), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 11.5× Fubotv Inc's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fubotv Inc for 35 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| FUBO | GMED | |
|---|---|---|
Market Cap | $894.32M | $10.25B |
Volume | 1,279,134 | 1,108,124 |
Sector | Media | Health |
52-Week High | $48.96 | $96.82 |
52-Week Low | $8.09 | $58.33 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | $1.07B | $9.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $8.26, down 5.49% on the day, reflecting a bearish technical trend. The stock shows deep undervaluation with a P/E of 2.13 and P/S of 0.16, but fundamentals are mixed with a net loss of $172.25M in 2024 despite revenue growth to $1.62B. Recent news highlights strategic partnerships, including NHL streaming deals and the launch of My Local Sports, aiming to boost subscriber growth and advertising revenue.
The outlook remains speculative; a projected net profit of $123M in 2025 suggests a potential turnaround, but persistent cash burn and high debt levels pose significant risks. Analyst consensus is divided with a $63.38 price target, indicating substantial upside if execution improves, yet the bearish technical signals and competitive pressures warrant caution for investors.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
